Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RA-18C3 (Bermekimab) in Moderate to Severe Acne Vulgaris
NCT01474798Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2012
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bermekimab in acne vulgaris, sponsored by Janssen Pharmaceutical. Primary endpoint: Safety and tolerability at 100 days. Started Feb 2012; status: completed.
02
Drugs
bermekimab
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT01474798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01474798.